SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to increased spending forecasts related to AI, drawing comparisons to the company's metaverse investments; the community is debating whether this dip represents a buying opportunity or signals deeper concerns about Meta's direction, with some citing a one-time tax charge as the primary driver, while others point to overall market weakness or algorithmic reactions.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the iconic Rage Guy meme, emphasizing a return to OG meme culture and community-driven growth. Discussions highlight the importance of belief and shared effort, with community members expressing bullish sentiment and encouraging each other to "RAGE ON" and "work for their bags". The movement is positioned as a cultural correction against soulless memecoins.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors anticipate the company's earnings report and how effectively it's monetizing data through AI partnerships. Community members are discussing revenue estimates, daily active user growth, and the potential for a post-earnings rally or selloff. Some are also pointing to potential connections with other trending stocks and broader market factors.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle ($CMG) is trending due to a significant drop following a lowered sales outlook, sparking discussions about consumer spending and the company's value proposition. Community members are debating whether the dip is a buying opportunity or a sign of deeper issues with the brand, citing concerns about pricing, portion sizes, and competition in the fast-casual dining sector.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV); discussions center on whether the deal undervalues CORZ, especially given the potential for AI infrastructure growth. Some shareholders believe CORZ is worth more as a standalone company, citing peers and potential for new contracts, while others worry about financial stability without the merger. The vote outcome is uncertain, leading to speculation about future directions and potential board changes.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

EBS is trending due to raised FY25 EBITDA guidance, sparking optimism about the company's future profitability. The community is discussing the potential for a significant stock re-rating and a short squeeze, with some highlighting the low P/E ratio relative to the broader market. Discussions also involve potential catalysts like government appropriations and debt refinancing.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members discuss the potential for a short squeeze, driven by high short interest and optimism around the company's pipeline. Chatter revolves around buyout speculation, comparisons to competitors, and anticipation for upcoming presentations at ObesityWeek. The stock's recent performance and market dynamics in the obesity treatment sector are also fueling the conversation.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed rumors of a potential buyout, sparking active discussions within the investment community. The speculation surfaces as the company focuses on oncology and prepares to report earnings in November. Community members are weighing the potential deal price and strategic implications for Moderna's future.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is trending as investors digest recent earnings and a reduced dividend, leading to a sharp price decline. The community is debating whether this presents a value opportunity or signals deeper challenges for the company, with some citing an overreaction and oversold conditions. Bullish sentiment is building around potential for a price rebound given its inclusion in the S&P 500.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending due to upcoming Phase 3 data for its DMD treatment, with investors closely watching for positive results that could lead to FDA approval; community chatter reflects both excitement and apprehension, as the data represents a pivotal moment for the company. Community members also highlight BlackRock's substantial stake in Capricor. Some traders cite the potential for a significant short squeeze based on the stock's high short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UnitedHealth Lifts EPS Outlook Despite Mixed Q3 Results: ETFs in Focus

UNH posts mixed Q3 results with a revenue miss but lifts its 2025 EPS outlook, boosting interest in healthcare ETFs like IHF and XLV. 

<ul class="summary-bullets"><li>Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with semaglutide.</li><li>The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026. &nbsp;</li></ul>Neumora Therapeutics, Inc. (NMRA) on Monday announced positive data from preclinical studies for its experimental weight-loss therapy NMRA-215.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174401/0/en/Neumora-Therapeutics-Announces-Class-Leading-Weight-Loss-Demonstrated-with-NMRA-215-in-Preclinical-Diet-Induced-Obesity-Model.html">said</a> that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide in mice with diet-induced obesity. Semaglutide is the active ingredient in Novo Nordisk’s (NVO) popular weight-loss drug Wegovy.<h2 class="st-heading-2">Plans Ahead</h2>NMRA-215 is an oral NLRP3 inhibitor in development for the treatment of obesity. It blocks the activity of the NLRP3 inflammasome, a protein complex involved in the immune response to inflammation. NLRP3-mediated neuroinflammation in the hypothalamus is linked to obesity, Neumora noted.The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company jumped about 22% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NMRA">NMRA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<blockquote>“These data demonstrate NMRA-215 drives meaningful weight loss as a monotherapy in mice, including incretin-like induction, additive weight loss in the combination setting with semaglutide, as well as the potential to enable incretin-sparing dosing regimens.” – Paul Berns, CEO, Neumora Therapeutics</blockquote>Separately, Neumora on Monday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174424/0/en/Neumora-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Study-of-M4-Positive-Allosteric-Modulator-NMRA-898.html">announced</a> the initiation of an early-stage study of its NMRA-898 aimed at evaluating safety, tolerability, and human pharmacokinetic data of the compound for potential use in the treatment of schizophrenia and other neuropsychiatric disorders.&nbsp;NMRA stock is down by 75% this year and by about 78% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/eth-outperforms-btc-as-retail-sentiment-improves-ahead-of-fed-rate-decision/cLG030ZR3Mh">Ethereum Outperforms Bitcoin As Retail Sentiment Improves Ahead Of Fed Rate Decision, Trump-Xi Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies

Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide.

Equity

<ul class="summary-bullets"><li>The agency approved the medicine for both adults and pediatric patients with acute myeloid leukemia who are 1 year or older and have a susceptible nucleophosmin 1 (NPM1) mutation.</li><li>In the second quarter, Revuforj achieved $28.6 million in net revenue, representing a 43% increase over the first quarter of 2025. &nbsp;</li></ul>The U.S. Food and Drug Administration on Friday said that it has approved Syndax Pharmaceuticals’ (SNDX) Revuforj for some relapsed or refractory acute myeloid leukemia (ACL) patients with particular mutations.The agency <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation">approved</a> the medicine for both adults and pediatric patients one year and older with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. &nbsp;<h2 class="st-heading-2">Implication For Patients, Syndax</h2>According to Syndax, mutations in the NPM1 gene are the most common genetic alteration observed in AML, occurring in approximately 30% of adults with the condition. Patients with the mutation have a poor prognosis, and there are currently no approved therapies that selectively target the underlying disease mechanism driving the cancer, it said.Revuforj was launched in the U.S. in November 2024 for the treatment of a specific type of leukemia called relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. The new FDA approval expands the indication for the drug.In the second quarter, Revuforj achieved $28.6 million in net revenue, representing a 43% increase over the first quarter of 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company soared 4% on Friday morning at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNDX">SNDX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:583/60;" src="data:image/png;base64,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" width="583" height="60" alt="SNDX's Sentiment Meter and Message Volume as of 1:39 p.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>SNDX's Sentiment Meter and Message Volume as of 1:39 p.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the stock is a good buy below $20.<stembedurl>https://stocktwits.com/dcrown/message/633624243</stembedurl>Another raised doubts about the possibility of a major rally.<stembedurl>https://stocktwits.com/Olena/message/633527864</stembedurl>SNDX stock is up by 15% this year but down by about 20% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/teladoc-stock-shoots-up-bofa-views-it-as-differentiated-asset-but-cautious-on-near-term-outlook/cLGJuuUR3ti">Teladoc Stock Shot Up 8% Today: BofA Views It As Differentiated Asset But Remains Cautious On Near-Term Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval 

The agency approved the medicine for both adults and pediatric patients with acute myeloid leukemia who are 1 year or older and have a susceptible nucleophosmin 1 (NPM1) mutation.

Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs

Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs. 

Zacks Investment Ideas feature highlights: XLP, KXI, XLU, VPU, VHT and XLV

As AI-fueled markets show bubble risks, defensive ETFs like XLP, XLU, and XLV offer investors stability and downside protection.

 If the AI Bubble Bursts, Here Are Some Defensive ETFs to Consider 

As AI-fueled gains spark bubble warnings, investors are eyeing defensive ETFs in consumer staples, utilities and healthcare for safety. 

Should You Invest in the Vanguard Health Care ETF (VHT)?

Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?

AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs. 

Health and Human Services Secretary Robert F. Kennedy Jr. reportedly said in a Cabinet meeting attended by President Donald Trump on Tuesday that his department will announce "interventions" that he believes are causing autism."We will have announcements as promised in September," Kennedy said, as <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.nbcnews.com/politics/trump-administration/live-blog/trump-zelenskyy-putin-tariffs-dc-guard-redistricting-gaza-live-updates-rcna226792/rcrd87058?canonicalCard=true">reported</a> by NBC News. The Health Secretary said that the department is finding interventions that are “almost certainly causing autism” and said the announcement in September will address them.Kennedy is a prominent anti-vaccine activist. He had claimed during the pandemic that childhood vaccinations could lead to autism. In a January 2021 <a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/RobertKennedyJr/status/1352748139665645569?s=19">post</a> on X, he said Hank Aaron’s death about two weeks after he received Moderna, Inc.’s (MRNA) mRNA vaccine is part of a "wave of suspicious deaths among elderly closely following administration of #COVID #vaccines."<figure class="image"><img style="aspect-ratio:533/152;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_26_at_2_41_02_PM_png_ff490bd3a6.webp" alt="Screenshot 2025-08-26 at 2.41.02 PM.png" width="533" height="152"><figcaption>Screenshot of Kennedy's X Post from Jan 22, 2021</figcaption></figure>He also fired members of the Centers for Disease Control and Prevention’s panel of vaccine experts in June. "Today we are prioritizing the restoration of public trust above any specific pro- or anti-vaccine agenda," Kennedy said in a statement then.Earlier this month, his department also announced plans to cancel $500 million in funding for mRNA vaccines under development to treat diseases such as the flu.“BARDA (Biomedical Advanced Research and Development Authority) is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We’re shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate,” Kennedy said about the decision. “We reviewed the science, listened to the experts, and acted,” he added.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-stock-rallies-after-therapy-for-autoimmune-disease-meets-late-stage-trial-goals/chsvb4wRdjv">Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. speaks during a roundtable discussion on soil health in the Mike Mansfield Room at the U.S. Capitol. (Photo by Michael M. Santiago/Getty Images)

Kennedy Jr. Says Health And Human Services Will Address ‘Interventions’ That Cause Autism

The HHS Secretary promised an announcement in September to address these interventions.

Insights Into 13F Filings: ETFs to Invest in Like Billionaires

Hedge funds invest in Microsoft, UnitedHealth and homebuilders. ETFs like MAGS, IHF and XHB let you invest like billionaires.

Vanguard Group, Inc. - Vanguard Health Care ETF

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

VHT
Vanguard Health Care ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VHT News

VHTVanguard Health Care ETF